



Press release

**Order backlog up by 66%:
€18.26M at the end of June 2015**

SOPHIA ANTIPOLIS, France – September 17, 2015 – MEDIAN Technologies (ALMDT), a leading medical imaging solutions and service provider for image interpretation and management in oncology, announces a strong growth of its order backlog (*) in H1 2015.

As at June 30 2015, MEDIAN Technologies' order backlog was of €18.26M. As a reminder, the company's order backlog was of €11M as at December 31 2014, which represents a 66% growth recorded during the first half of 2015.

This growth illustrates MEDIAN Technologies' business dynamism. It also provides good visibility regarding the future of the company.

() Order backlog refers to customers' orders that have been received but not invoiced yet.*



About MEDIAN Technologies: MEDIAN Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. MEDIAN Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. MEDIAN serves two primary markets: drug development and patient care. MEDIAN has a strategic partnership with the world's largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to

biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.

Founded in 2002, MEDIAN Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. MEDIAN has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia. MEDIAN has received the label "Innovative company" by the BPI and is listed on Euronext Paris' Alternext market. ISIN: FR0011049824– ticker: ALMDT. The company is eligible for the PEA PME SME equity savings plan setup. For more information on MEDIAN, please visit: www.mediantechologies.com

"We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients."



Contacts

MEDIAN Technologies Fredrik Brag, CEO +33 4 92 90 65 82 fredrik.brag@mediantechnologies.com	Press ALIZE RP Caroline Carmagnol + 33 1 44 54 36 66 median@alizerp.com	Investors ACTIFIN Ghislaine Gasparetto ggasparetto@actifin.fr +33 1 56 88 11 11
--	---	---